ArticleNuclear medicine communications2025
Clinical value of multiparameters of 2-[ 18 F]-fluoro-2-deoxy-glucose PET/MRI in tumor/lymph node staging of esophageal squamous cell carcinoma.
Article in Nuclear medicine communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of PET-detected nodal upstaging and planning target volume expansion in esophageal cancer radiotherapy planning.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to determine the role of integrated 2-[ 18 F]-fluoro-2-deoxy-glucose ( 18 F-FDG) PET/MRI in preoperative T and N staging and prognosis of esophageal squamous cell carcinoma (ESCC). MATERIALS AND
methodsThe analysis was conducted on 66 ESCC patients who accepted 18 F-FDG-PET/MRI examinations per-operatively. We select the primary lesion as the region of interest to evaluate the diagnostic efficiency of T and N staging. Univariate and stepwise multivariate logistic regression models were performed to determine the T and N staging factors, and we established the optimal prediction model by using the Akaike information criterion. Finally, Cox regression was used for the early recurrence analyses.
resultsThe total lesion glycolysis (TLG), metabolic tumor volume (MTV), minimum apparent diffusion coefficient (ADC min ), and mean apparent diffusion coefficient (ADC mean ) were significant in univariate analysis with T staging. None of the parameters were significant in the univariate analysis with N staging. Cox regression validated that this model-combining TLG (>47.5), MTV (>9.4 cm 3 ), ADC min (<1.49 × 10 -3 mm 2 /s), and ADC mean (<1.68 × 10 -3 mm 2 /s)-was the sole predictor significant associated with early tumor recurrence. Notably, no association was found between any single variable and early tumor recurrence.
conclusionIntegrated 18 F-FDG PET/MRI is feasible for preoperative T and N staging of ESCC. The optimal model is composed of TLG, MTV, ADC min, and ADC mean -all parameters derived from 18 F-FDG-PET/MRI-which not only provide valuable information for T staging but also predict early recurrence within the first postoperative year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.